PCV20: Clinical Trials

2 active not recruiting, 2 completed, 2 not yet recruiting. 6 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	6	Active not recruiting 2, Completed 2, Not yet recruiting 2
Phase 2	1	Completed 1

Follow PCV20: new trials by email Literature Review of PCV20 trials Research Report on PCV20

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial	Phase 1	Not yet recruiting	GlaxoSmithKline	60	2027-01-25	2026-07-16
A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial	Phase 1	Active not recruiting	GlaxoSmithKline	46	2026-05-15	2026-09-28
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial	Phase 1	Active not recruiting	GlaxoSmithKline	122	2026-03-10	2026-10-27
A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age Pn-MAPS30plus, PCV20 - Pneumonia, Bacterial	Phase 1	Completed	GlaxoSmithKline	127	2025-08-12	2026-06-05
Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant PCV-LITE, PCV-LITE+LVA, PCV20 - Vaccine Reaction	Phase 1	Not yet recruiting	LiteVax BV	80	2025-07-01	2025-05-22
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine - Pneumococcal Vaccines	Phase 1 / Phase 2	Completed	Vaxcyte, Inc.	1015	2023-11-08	2025-07-28

Conditions studied

Pneumonia, Bacterial (4)

Sponsors

GlaxoSmithKline (4)  ·  LiteVax BV (1)  ·  Vaxcyte, Inc. (1)

Countries

Australia (2)  ·  South Africa (1)  ·  United States (1)

Results publications

PMID 41864214